Bristol Myers Squibb Company
NEWS
Abingworth Bioventures closed out its latest investment fund aimed at supporting life science companies with $315 million. The latest fund, ABV VII, will be used to support investments in Europe and the United States.
Martin Shkreli has been blogging about the biopharma industry from prison.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
It’s time for some pharmaceutical prognostication. EvaluatePharma released its forward-looking report to 2024 that includes predictions of the best-selling prescription drugs.
Roche announced that its Phase III IMpassion130 clinical trial met its co-primary endpoint of progression-free survival (PFS) in triple-negative breast cancer (TNBC).
Akero Therapeutics, headquartered in Cambridge, Massachusetts, closed on a $65 million Series A financing round.
Roche announced that its Phase III IMpower 133 clinical trial of Tecentriq (atezolizumab) plus carboplatin and etoposide chemotherapy met its co-primary endpoints.
AbbVie and the Keck Graduate Institute (KGI) School of Pharmacy have partnered to form the first AbbVie-KGI Biopharmaceutical Industry Fellowship.
Biogen signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.
JOBS
IN THE PRESS